Because in the western blot analysis tau was fragmented to a degree that the quantitation of ptau/total tau was not feasible, we used a multiplex ELISA assay to quantify both total tau and ptau (T231), a phosphorylation site identified in AD brains [41, 42] to determine potential effects on hyperphosphorylation. The gene discussed is MAPT; the disease is Alzheimer disease.